MariTide explained

Drug Name:	Maridebart cafraglutide
Synonyms:	AMG 133
Legal Status:	Investigational
Cas Number:	2760218-55-9
Unii:	Z24U3U73HN

MariTide, also known as maridebart cafraglutide^[1] (developmental name AMG 133), is an investigational drug developed by Amgen for the treatment of obesity. It is an agonist of the GLP-1 receptor and an antagonist of the GIPR. In a preliminary trial, AMG 133 resulted in a 14.5 percent weight loss after 12 weeks at the highest dose tested.^{[2] [3] [4]}

Notes and References

1. Web site: Beasley . Deena . Amgen taking different path to weight loss windfall . Reuters . 2024-02-06 . 2024-03-06.
2. Hammoud . Rola . Drucker . Daniel J. . Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1 . Nature Reviews Endocrinology . April 2023 . 19 . 4 . 201–216 . 10.1038/s41574-022-00783-3 . en . 1759-5037.
3. Jepsen . Mathies M. . Christensen . Mikkel B. . Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity . Expert Opinion on Emerging Drugs . 3 July 2021 . 26 . 3 . 231–243 . 10.1080/14728214.2021.1947240.
4. Bailey . Clifford J. . Flatt . Peter R. . Conlon . J. Michael . An update on peptide-based therapies for type 2 diabetes and obesity . Peptides . 1 March 2023 . 161 . 170939 . 10.1016/j.peptides.2023.170939 . 0196-9781. free .